S.3187 - Food and Drug Administration Safety and Innovation Act

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. view all titles (24)

All Bill Titles

  • Short: Food and Drug Administration Safety and Innovation Act as passed house.
  • Short: Biosimilar User Fee Act of 2012 as passed house.
  • Short: Generic Drug User Fee Amendments of 2012 as passed house.
  • Short: Medical Device User Fee Amendments of 2012 as passed house.
  • Short: Prescription Drug User Fee Amendments of 2012 as passed house.
  • Short: Synthetic Drug Abuse Prevention Act of 2012 as passed house.
  • Short: Food and Drug Administration Safety and Innovation Act as passed senate.
  • Short: Biosimilar User Fee Act of 2012 as passed senate.
  • Short: Generic Drug User Fee Amendments of 2012 as passed senate.
  • Short: Medical Device User Fee Amendments of 2012 as passed senate.
  • Short: Prescription Drug User Fee Amendments of 2012 as passed senate.
  • Short: Synthetic Drug Abuse Prevention Act of 2012 as passed senate.
  • Official: A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. as introduced.
  • Short: Food and Drug Administration Safety and Innovation Act as introduced.
  • Short: Biosimilar User Fee Act of 2012 as introduced.
  • Short: Generic Drug User Fee Amendments of 2012 as introduced.
  • Short: Medical Device User Fee Amendments of 2012 as introduced.
  • Short: Prescription Drug User Fee Amendments of 2012 as introduced.
  • Short: Food and Drug Administration Safety and Innovation Act as enacted.
  • Short: Biosimilar User Fee Act of 2012 as enacted.
  • Short: Generic Drug User Fee Amendments of 2012 as enacted.
  • Short: Medical Device User Fee Amendments of 2012 as enacted.
  • Short: Prescription Drug User Fee Amendments of 2012 as enacted.
  • Short: Synthetic Drug Abuse Prevention Act of 2012 as enacted.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.


All Votes

Result: Amendment Rejected - May 24, 2012

Roll call number 105 (Amendment number S.Amdt 2111) in the Senate

Question: On the Amendment S.Amdt. 2111 to S. 3187 (No short title on file)

Amendment purpose: To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.

 

Vote on This Bill

50% Users Support Bill

4 in favor / 4 opposed
 

Send Your Senator a Letter

about this bill Support Oppose Tracking
Track with MyOC

Top-Rated Comments